Cite
HARVARD Citation
Elsada, A. et al. (2021). A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England. EJHaem. 2 (3), pp. 493-497. [Online].